Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: A meta-analysis of 5 randomized begin trials

Endocrine Practice

Volumn 20, Issue 4, 2014, Pages 285-292

  Rodbard, Helena W ^a   Gough, Stephen ^b   Lane, Wendy ^c   Korsholm, Lars ^d   Bretler, Ditte Marie ^d   Handelsman, Yehuda ^e  

^a Endocrine and Metabolic Consultants   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Mountain Diabetes and Endocrine Center   (United States)

^d NOVO NORDISK A S   (Denmark)

^e Metabolic Institute of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ARTICLE; BODY WEIGHT; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; RISK;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84898648419     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13287.OR     Document Type: Article

References (17)

1. Garber AJ. Hypoglycaemia: A therapeutic concern in type 2 diabetes. Lancet. 2012;379:2215-2216.
2. Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA: American Diabetes Association; 2009.
3. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-Adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14:1081-1087.
4. Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J. 2009;102:67-76.
5. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-Acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
6. Heller S, Buse J, Fisher M, et al BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-To-Target non-inferiority trial. Lancet. 2012;379: 1489-1497.
7. Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-long-Acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-To-Target non-inferiority trial. Lancet. 2012;379:1498-1507.
8. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-To-Target trial (BEGIN Once Long). Diabetes Care. 2012;35: 2464-2471.
9. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal R. Low-volume insulin degludec 200 U/ml once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-To-Target trial: The BEGIN LOW VOLUME trial). Diabetes Care. 2013; 36:2536-2542.
10. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomised, controlled, Pan-Asian, treat-To-Target trial. J Diabetes Investig. 2013;4(6):605-612.
11. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-To-Target trial in people with type 2 diabetes. Diabetes Care. 2013;36:858-864.
12. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-Analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-184.
13. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-Acting insulin degludec. Clin Drug Investig. 2013;33: 515-521.
14. Heise T, Nosek L, Bøttcher S, Hastrup H, Haahr H. Ultra-long-Acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
15. Wutte A, Plank J, Bodenlenz M, et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007; 115:461-467.
16. Heise T, Hövelmann U, Nosek L, et al. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 2011; 60:LB11 [Abstract 37-LB].
17. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14:859-864.